Company news

Kodiak Sciences Inc news in 2023

Kodiak Sciences Inc's news releases, calls and decks from 2023, newest first.

View company

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 20, 2023

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

November 13, 2023

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

November 5, 2023

Kodiak Sciences announces first time presentation of primary endpoint data from tarcocimab tedromer Phase 3 GLOW study in patients with diabetic retinopathy at American Academy of ophthalmology annual meeting

October 31, 2023

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

October 10, 2023

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 7, 2023

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

September 6, 2023

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

August 13, 2023

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

July 23, 2023

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

May 14, 2023

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

April 20, 2023

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

April 2, 2023

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

March 27, 2023

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

February 8, 2023

Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Decks in 2023